ArticleFrontiers in pharmacology2025

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.

Juan Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.